Dostarlimab (Jemperli®). HTA ID: 21045

Assessment Status NCPE Assessment Process Complete
HTA ID 21045
Drug Dostarlimab
Brand Jemperli®
Indication Indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.
Assessment Process
Rapid review commissioned 26/10/2021
Rapid review completed 30/11/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dostarlimab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 22/12/2021
Full submission received from Applicant 16/06/2022
Preliminary review sent to Applicant 22/11/2022
NCPE assessment re-commenced 20/12/2022
Follow-up to preliminary review sent to Applicant 08/02/2023
NCPE assessment re-commenced 10/02/2023
Factual accuracy sent to Applicant 27/02/2023
NCPE assessment re-commenced 10/03/2023
NCPE assessment completed 27/03/2023
NCPE assessment outcome The NCPE recommends that dostarlimab not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.